Simeprevir or telaprevir with peginterferon and ribavirin for recurrent hepatitis C after living-donor liver transplantation: A Japanese multicenter experience

Yoshihide Ueda, Toru Ikegami, Akihiko Soyama, Nobuhisa Akamatsu, Masahiro Shinoda, Kohei Ishiyama, Masaki Honda, Shigeru Marubashi, Hideaki Okajima, Tomoharu Yoshizumi, Susumu Eguchi, Norihiro Kokudo, Yuko Kitagawa, Hideki Ohdan, Yukihiro Inomata, Hiroaki Nagano, Ken Shirabe, Shinji Uemoto, Yoshihiko Maehara

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Aim: This study aimed to clarify the efficacy and safety of simeprevir, a second-generation NS3/4A inhibitor, with peginterferon and ribavirin for recurrent hepatitis C after liver transplantation. Methods: A retrospective cohort study of living-donor liver transplant recipients with recurrent hepatitis C with the hepatitis C virus genotype 1 treated with either simeprevir- or telaprevir-based triple therapy was carried out at eight Japanese liver transplant centers. Results: Simeprevir- and telaprevir-based triple therapies were given to 79 and 36 patients, respectively. Of the 79 patients treated with simeprevir-based triple therapy, 44 (56%) achieved sustained virological response 12 weeks (SVR12) after treatment ended, and there was no significant difference in the SVR12 between the simeprevir- and telaprevir-based triple therapy groups (69%). The rates of adverse events were not significantly different between the simeprevir- and telaprevir-based triple therapy groups, although the rate of patients who received blood cell transfusion and erythropoietin due to anemia and had renal insufficiency were significantly higher in the telaprevir group than in the simeprevir group. Three baseline factors, the presence of prior dual therapy with peginterferon and ribavirin (P = 0.001), a non-responder to the prior dual therapy (P < 0.001), and male sex (P = 0.040), were identified as significant predictive factors for non-SVR with simeprevir-based triple therapy. Conclusion: Simeprevir-based triple therapy for recurrent hepatitis C after living-donor liver transplantation resulted in a high SVR rate and good tolerability, especially in treatment-naïve patients.

Original languageEnglish
Pages (from-to)1285-1293
Number of pages9
JournalHepatology Research
Volume46
Issue number13
DOIs
Publication statusPublished - 2016 Dec 1

Keywords

  • hepatitis C
  • liver transplantation
  • living donor
  • simeprevir
  • telaprevir

ASJC Scopus subject areas

  • Hepatology
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Simeprevir or telaprevir with peginterferon and ribavirin for recurrent hepatitis C after living-donor liver transplantation: A Japanese multicenter experience'. Together they form a unique fingerprint.

  • Cite this

    Ueda, Y., Ikegami, T., Soyama, A., Akamatsu, N., Shinoda, M., Ishiyama, K., Honda, M., Marubashi, S., Okajima, H., Yoshizumi, T., Eguchi, S., Kokudo, N., Kitagawa, Y., Ohdan, H., Inomata, Y., Nagano, H., Shirabe, K., Uemoto, S., & Maehara, Y. (2016). Simeprevir or telaprevir with peginterferon and ribavirin for recurrent hepatitis C after living-donor liver transplantation: A Japanese multicenter experience. Hepatology Research, 46(13), 1285-1293. https://doi.org/10.1111/hepr.12684